Zonisamide for Fibromyalgia & Migraine

This study has been completed.

Sponsors and Collaborators:	University of Pittsburgh Eisai Medical Research Inc.
Information provided by:	University of Pittsburgh
ClinicalTrials.gov Identifier:	NCT00259636

Purpose

Patients with fibromyalgia & migraine are randomized to receive zonisamide or placebo.

Condition	Intervention	Phase
Fibromyalgia Migraine	Drug: zonisamide	Phase IV

MedlinePlus related topics: Fibromyalgia Headache Migraine

Drug Information available for: Zonisamide

Study Type:	Interventional
Study Design:	Randomized, Double-Blind, Placebo Control, Parallel Assignment
Official Title:	Zonisamide for Fibromyalgia & Migraine

Further study details as provided by University of Pittsburgh:

Primary Outcome Measures:

Secondary Outcome Measures:

Estimated Enrollment:	50
Study Start Date:	August 2004
Primary Completion Date:	January 2008 (Final data collection date for primary outcome measure)

Eligibility

Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Both

Criteria

Inclusion Criteria:

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00259636

Locations

United States, Pennsylvania
University of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15206

Sponsors and Collaborators

University of Pittsburgh

Eisai Medical Research Inc.

Investigators

Principal Investigator:

Dawn Marcus, MD

University of Pittsburgh

More Information

Study ID Numbers:	EISAI 51-345-749
Study First Received:	November 26, 2005
Last Updated:	November 11, 2008
ClinicalTrials.gov Identifier:	NCT00259636
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Fibromyalgia
Myofascial Pain Syndromes
Zonisamide
Central Nervous System Diseases
Pain
Headache Disorders, Primary
Rheumatic Diseases

Brain Diseases
Headache Disorders
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Diseases
Migraine Disorders
Headache

Additional relevant MeSH terms:

Antioxidants
Molecular Mechanisms of Pharmacological Action
Therapeutic Uses
Physiological Effects of Drugs
Nervous System Diseases

Central Nervous System Agents
Protective Agents
Anticonvulsants
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 14, 2009